Three new cases of bullous pemphigoid during anti-PD-1 antibody therapy

Abstract

Anti-programmed death 1 (PD-1) antibodies are revolutionizing the treatment of many cancers, including melanoma ¹. Cutaneous adverse events (AE) of anti-PD-1 antibodies are common (20%) and mainly non-specific. Bullous pemphigoids (BP) are very rare immune-related AEs induced by anti-PD-1 antibodies, with only 12 cases previously published. We report here three new cases of BP during anti PD-1 therapy with nivolumab.

This article is protected by copyright. All rights reserved.

http://ift.tt/2iP1HCY